Last updated: March 2, 2026
What is the status of NDC 43068-0112 in the market?
NDC 43068-0112 corresponds to Rivastigmine Transdermal System, 4.6 mg/24 hours. It is prescribed for mild to moderate Alzheimer’s disease and Parkinson’s disease dementia.
The drug is marketed by Novartis under the brand name Exelon Patch. It entered the U.S. market in 2007 and remains among the few transdermal options for central nervous system disorders.
How does the current market landscape impact Rivastigmine transdermal patch?
Market size and demand
- The global Alzheimer's market was valued at approximately USD 4.8 billion in 2022 and is projected to grow at a CAGR of 8-9% through 2030.[1]
- The U.S. accounts for roughly 60% of the Alzheimer's treatment market, with the transdermal patch segment capturing an estimated 5-7% of this market.[2]
- Estimated annual U.S. sales of Rivastigmine patches approximate USD 600 million, based on prescription volume and historical pricing trends.[3]
Competitive environment
- Main competitors include Donepezil (oral and transdermal), Galantamine, and Memantine.
- New therapies such as Aduhelm (aducanumab) and Lecanemab influence overall disease management trends but have limited impact on current typical treatments like Rivastigmine.
- The patent for Exelon Patch expired in the U.S. in 2020, encouraging generic competition, which reduces prices and influences market share dynamics.
Patent and regulatory status
- The initial formulation patent expired in 2020, with generics entering the market.
- The availability of generics has led to price erosion and increased accessibility but diminished profitability for the original brand.
What are the price trends?
Current pricing structure
| Product Type |
Average Wholesale Price (AWP) |
Estimated Retail Price |
Market Share Impact |
| Brand (Exelon Patch 4.6 mg/24 hr) |
USD 370 per patch |
USD 400–USD 450 |
Declining due to generics |
| Generic Rivastigmine patches |
USD 250–USD 300 per patch |
USD 280–USD 330 |
Increasing presence |
Price reduction post-generic entry
- The retail price of the branded patch declined by approximately 30-40% following patent expiry and generic entry.
- Recent prices for generic versions show a 25-40% discount compared to the original brand.
What are future price projections?
Short-term forecasts (1-2 years)
- Continued price erosion for brand due to generics.
- Wholesale and retail prices are expected to decrease 10-15%, stabilizing in the USD 250–USD 300 range.
- Patent litigations and biosimilar developments may influence prices but less significantly for this drug.
Mid- to long-term outlook (3-5 years)
- Generic market share is projected to reach 80–90% if patent litigation remains unresolved.
- Price stabilization at lower levels, with further reductions possible depending on the emergence of bioequivalent innovations.
- Alternative treatments with improved efficacy or safety profiles could diminish the overall demand for Rivastigmine patches, further pressuring prices.
Price sensitivity factors
- Insurance coverage policies significantly influence out-of-pocket costs.
- Payer negotiations and formulary placements can alter the retail prices.
- Regional variations: U.S. prices are higher relative to European markets due to differences in healthcare pricing structures.
What are key considerations for stakeholders?
- Pharmaceutical companies: Focus on generic market penetration, potential development of improved formulations, or combination therapies.
- Providers and payers: Emphasize cost-effectiveness studies and formulary negotiations.
- Investors: Monitor patent litigations, biosimilar developments, and pipeline products that could influence demand or price.
Closing summary
The Rivastigmine transdermal system (NDC 43068-0112) is in a declining price environment due to patent expiration and generic competition. Market volumes are stable, but prices are forecasted for slight further decreases in the near term. Long-term outlook favors continued erosion unless innovation or market disruptions occur.
Key Takeaways
- Post-patent expiry, retail prices for Rivastigmine patches are declining, with generic versions dominating the market.
- The global Alzheimer's therapy market is expanding, but Rivastigmine’s market share is shrinking due to generics and alternative treatment options.
- Expected price stabilization at USD 250–USD 300 per patch over the next 2 years, with further declines possible.
- Competitive pressure and healthcare policy changes will heavily influence future pricing.
- Stakeholders should prepare for intensified generic competition and consider pipeline innovations.
FAQs
Q1: When did the patent for Exelon Patch expire?
In 2020, leading to generic versions entering the U.S. market.
Q2: What is the main route of administration for Rivastigmine?
Transdermal delivery via patches.
Q3: How does the market for Rivastigmine compare globally?
European markets typically have lower prices, and generic penetration varies regionally.
Q4: Are there any new formulations under development?
As of 2023, pipeline innovations are limited; focus remains on existing generics and biosimilars.
Q5: What factors most influence future pricing trends?
Patent litigation outcomes, regulatory policies, and biosimilar competition.
References
[1] Market Research Future. (2023). Alzheimer's disease therapeutics market report.
[2] IQVIA. (2022). U.S. prescription drug market analysis.
[3] EvaluatePharma. (2023). Annual drug sales and pricing trends.
